NCT07021989 2026-03-17
ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma
University of California, San Francisco
Phase 2 Not yet recruiting
Clinical Trials
21 trialsNCT05300282 2026-01-28
FIL_A-BEGEV
Fondazione Italiana Linfomi - ETS
Phase 1/2 Recruiting
NCT03618550 2025-12-02
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06377566 2025-04-20
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06211881 2024-01-18
Chi-GVM Regimen for the Treatment of R/R PTCL
The First Affiliated Hospital with Nanjing Medical University
Phase NA Unknown
NCT00574496 2023-09-28
Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00003963 2020-08-03
Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell Transplantation
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT00632827 2020-04-27
Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)
University of California, San Francisco
Phase 2 Terminated
NCT04021992 2019-08-06
GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL
Sun Yat-sen University
Phase 2 Unknown
NCT00392691 2019-05-15
Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment
Swiss Cancer Institute
Phase 1 Completed
NCT00388349 2017-06-14
Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease
Stanford University
Phase 2 Completed
NCT00881387 2016-12-15
Rituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to Treatment
University of Miami
Phase 2 Withdrawn
NCT00920153 2016-09-16
Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma
French Innovative Leukemia Organisation
Phase 3 Terminated
NCT00006029 2016-07-14
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
Alliance for Clinical Trials in Oncology
Phase 1/2 Completed
NCT00225173 2014-08-27
Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease
Stanford University
Phase 2 Terminated
NCT01884428 2014-01-29
Study of Combination of PIGEV Before Autologous Stem Cell Transplant in Patients With Hodgkin's Lymphoma
Istituto Clinico Humanitas
Phase 1 Unknown
NCT01884441 2014-01-29
Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients
Istituto Clinico Humanitas
Phase 2 Unknown
NCT00462787 2013-11-14
Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Leukemia
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00842595 2013-07-24
Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive Lymphomas
French Innovative Leukemia Organisation
Phase 2 Completed
NCT00004105 2011-03-28
Combination Chemotherapy in Treating Patients With Advanced Cancer
NYU Langone Health
Phase 1/2 Completed
NCT00636311 2010-09-02
A Phase II Study of IGEV +/- Bortezomib Before Hign Dose Consolidation in Relapsed/Refractory Hodgkin's Lymphoma
Istituto Clinico Humanitas
Phase 2 Completed